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Abstract
Purpose: The diagnosis and monitoring of liver fibrosis is an important clinical
issue; however, this is usually achieved by invasive methods such as biopsy. We
aimed to determine whether histogram analysis of hepatobiliary phase images of
gadoxetic acid-enhanced magnetic resonance imaging (MRI) can provide non-
invasive quantitative measurement of liver fibrosis.
Methods: This retrospective study was approved by the institutional ethics
committee, and a waiver of informed consent was obtained. Hepatobiliary phase
images of preoperative gadoxetic acid-enhanced MRI studies of 105 patients (69
males, 36 females; age 56.1¡12.2) with pathologically documented liver fibrosis
grades were analyzed. Fibrosis staging was F0/F1/F2/F3/F4 (METAVIR system) for
11/20/13/15/46 patients, respectively. Four regions-of-interest (ROI, each about 2
cm2) were placed on predetermined locations of representative images. The
measured signal intensity of pixels in each ROI was used to calculate corrected
coefficient of variation (cCV), skewness, and kurtosis. An average value of each
parameter was calculated for comparison. Statistical analysis was performed by
ANOVA, receiver operating characteristic (ROC) curve analysis, and linear
regression.
Results: The cCV showed statistically significant differences among pathological
fibrosis grades (P,0.001) whereas skewness and kurtosis did not. Univariable
linear regression analysis suggested cCV to be a meaningful parameter in
predicting the fibrosis grade (P,0.001, b50.40 and standard error 50.06). For
discriminating F0-3 from F4, the area under ROC score was 0.857, standard
deviation 0.036, 95% confidence interval 0.785–0.928.
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Conclusion: Histogram analysis of hepatobiliary phase images of gadoxetic acid-
enhanced MRI can provide non-invasive quantitative measurements of hepatic
fibrosis.
Introduction
Liver fibrosis is a common response to almost any kind of chronic hepatic insult.
If the underlying chronic pathology is uncorrected, progressive inflammation and
fibrosis may lead to liver cirrhosis [1]. The degree of liver fibrosis is a critical
factor that substantially influences the prognosis and clinical management of
chronic liver diseases. Therefore accurate assessment of liver fibrosis is essential
[2]. Although liver biopsy is the gold standard for evaluating hepatic fibrosis, it
has several limitations such as invasiveness, patient compliance, potential
sampling errors and intra/inter-observer variations [1–4]. Consequently, demands
for less invasive and more feasible methods have stimulated research on imaging-
based approaches for fibrosis measurement.
Recently, several liver fibrosis measurement methods based on image analysis
such as ultrasound transient elastography and magnetic resonance (MR)
elastography have been established [1]. Although promising, these methods
require dedicated equipment and additional diagnostic procedures. It would be
useful if fibrosis measurement can be accomplished using widely available imaging
modalities such as routine magnetic resonance imaging (MRI). Several reports
suggested that the relative enhancement profiles of gadoxetic acid-enhanced MRI
may be useful to predict the severity of hepatic fibrosis [5–8]. However, the values
of relative enhancement represent the degree of hepatocyte malfunction caused by
fibrosis rather than the fibrosis itself [8].
It has been suggested that texture analysis of liver MRI may be useful to predict
liver cirrhosis and/or fibrosis grade [9]. Gadoxetic acid is a hepatocyte specific
contrast agent that is gradually taken up by hepatocytes after injection [10, 11].
We postulated that in the absence of fibrosis, the liver texture would appear
considerably homogeneous and the degree of liver enhancement on hepatobiliary
phase would be mostly determined by the hepatocytes (which actively uptake
gadoxetic acid). However, as fibrosis progresses, the functional hepatocytes and
non-functional fibrosis become intermingled, and consequently the hepatobiliary
phase liver enhancement would become heterogeneous. Therefore, we hypothe-
sized that if the liver is normal, it would appear homogeneously bright, whereas a
fibrotic liver would appear heterogeneous due to pixels with varying signal
intensities (Figure 1). The purpose of this study was to investigate whether
histogram analysis of hepatobiliary phase gadoxetic acid-enhanced MRI can be
applied as a method for quantitative index to measure liver fibrosis.
Histogram Analysis of Hepatic Fibrosis
PLOS ONE | DOI:10.1371/journal.pone.0114224 December 2, 2014 2 / 15
Materials and Methods
Study Population
The ethics committee of our institution approved this retrospective study, and a
waiver of informed consent was obtained. We first searched for patients who
underwent any kind of liver surgery between June 2010 to December 2011, and
had a preoperative gadoxetic acid-enhanced MRI performed on a single allocated
unit. This process identified 341 candidate cases. The exclusion criteria were as
follows: (a) MRI performed earlier than 30 days prior to surgery (n5152); (b)
patients who received any kind of anti-cancer treatment (e.g., radiation therapy or
chemotherapy), (n546); (c) patients diagnosed with a systemic disease that might
potentially influence the liver (e.g., iron deficiency anemia or metabolic disorder),
(n516); (d) patients who received an operation which interfered with or made
assessment of the background liver parenchyma suboptimal (e.g., intra-operative
radiofrequency ablation or wedge resection), (n59); (e) incomplete clinical
information (e.g., blood chemistry results within 2 weeks of MRI not available),
(n55); (f) presence of focal lesions at predetermined locations where regions of
interest (ROI) should be placed (n55); or (g) presence of artifacts causing
significant image corruption of the background liver parenchyma interfering with
reliable ROI sampling (n53). This process defined a study population of 105
patients (Figure 2), 69 males and 36 females with documented pathological
fibrosis grades. Mean age was 56.1¡12.2 years. The underlying indications for
surgery were hepatocellular carcinoma (n575), cholangiocarcinoma (n55),
hepatic metastasis from colorectal cancer (n515), stomach cancer (n53), and
Figure 1. Hypothetical schematic of the concept of histogram analysis as a method for liver fibrosis
evaluation. The histologic images (left column, Eosin and Masson-Trichrome stain) of (A) normal liver and (B)
cirrhotic liver. An imaginary rectangular region of interest (ROI) drawn on gadoxetic acid enhanced MRI
hepatobiliary phase image shows 12 pixels corresponding to the left column image (middle column). A plotted
histogram (right column; x-axis, signal intensity; y-axis, frequency) of hypothetical hepatobiliary phase image.
Note that the cirrhotic liver would display heterogeneous hepatobiliary phase images, which is reflected in
histogram as a wider graph with a blunted peak.
doi:10.1371/journal.pone.0114224.g001
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rectal carcinoid (n51). Benign conditions such as hemangioma (n51), focal
nodular hyperplasia (n51), angiomyolipoma (n51), liver cirrhosis (n51), and
healthy liver donors (n52) were also included. B viral hepatitis (n566) was the
most frequent etiology of chronic hepatitis in our study population, followed by C
viral hepatitis (n53) and alcoholic hepatitis (n53), while 33 patients did not have
an identifiable underlying chronic liver disease. Serum levels of bilirubin, aspartate
aminotransferase, alanine aminotransferase, and creatinine obtained within 2
weeks before MRI were recorded (Table 1). The pathology report of liver
resection or explanation was reviewed, and the liver fibrosis grade (classified
according to the METAVIR system) of the tumor free liver of each patient was
recorded.
Image acquisition
MR images were obtained on a single 3-T imaging unit (Magnetom Tim Trio;
Siemens Medical Solutions, Erlangen, Germany). The MRI protocol at our
institution consisted of a breath-hold transverse T1-weighted in- and out-of-
phase 2-dimensional (D) gradient-echo (GRE) sequence (TR/in phase TE, 150/2.4
msec; out-of-phase TE, 1.2 msec; flip angle, 65 ;˚ FOV, 32–38625–29 cm; matrix,
2566256; section thickness, 6 mm; slice spacing, 1.2 mm; one signal acquired;
Figure 2. An illustrative summary of the inclusion and exclusion criteria of which we used to define the study population.
doi:10.1371/journal.pone.0114224.g002
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number of slices, 30), a breath-hold transverse 3D GRE (TR/TE, 2.5/0.9 msec; flip
angle, 13 ;˚ FOV, 32–36625–36 cm; matrix, 3206224; section thickness, 2 mm;
no gap; acquisition time, 23 seconds) and a single-shot turbo spin-echo (TR/TE,
466/148; FOV, 32–36625–29 cm; matrix, 2886230; section thickness, 4 mm;
slice spacing, 1 mm) with spectral fat suppression technique. Parallel imaging
with generalized autocalibrating partially parallel acquisition with an acceleration
factor of 2 was applied to improve image quality.
To determine the scan delay for arterial phase imaging, a test bolus technique
was used with a 1-mL injection volume. Contrast-enhanced MRI was obtained
using a breath-hold 3D-GRE sequence after a 0.025 mmol/kg body weight IV
bolus of gadoxetic acid was administered at an injection rate of 2 mL/s followed
by a saline flush of 20 mL. Portal venous and transitional phase images were
obtained approximately 30–40 seconds after the acquisition of the previous phase
images; 20–35 s (arterial phase), 60–70 s (portal venous phase), and 100–120 s
and 150–180 s (transitional phase) after intravenous contrast injection. All images
were obtained in the transverse plane. Hepatobiliary phase images were acquired
between 15 to 20 minutes after gadoxetic acid was injected using identical
parameters.
Image analysis and parameters
The hepatobiliary phase MR images were archived in Digital Imaging and
Communications in Medicine (DICOM) format, and stored on a secondary
console containing the Osirix Digital Imaging and Communications in Medicine
viewer for Macintosh (Osirix, version 3.5.1; the Osirix Foundation, Geneva,
Switzerland). One abdominal radiologist (X.X, 2 years of experience in abdominal
imaging), blinded to clinical information and pathological fibrosis grades, placed
four circular 2 cm2 regions of interest (ROI) per patient. Two representative
images were selected at the level including a horizontal portion of the right hepatic
vein and the main portal vein, respectively. Two ROIs were selected in each
representative image at locations anterior and posterior to the right hepatic vein
Table 1. Serum chemistry profiles of the patients included in this study.
Category
Gender (M/












56/19 56.5¡10.5 0.72¡0.31 37.8¡22.7 38.3¡29.3 0.86¡0.20
Colorectal cancer (n515) 5/10 58.1¡12.0 0.52¡0.20 24.3¡21.8 17.7¡14.9 0.83¡0.25
Cholangiocarcinoma (n55) 3/2 62.0¡10.6 0.74¡0.34 33.6¡13.0 42.2¡18.9 0.84¡0.18
Stomach cancer* (n53) 3/0 61–75 0.6–1.0 28–52 30–60 0.85–0.91
Others (n57) 2/5 38.3¡17.9 0.63¡0.23 19.9¡7.5 18.1¡6.3 0.70¡0.18
Values are mean¡standard deviation, except for a group(*) that included too few patients to perform statistical analysis. In this group, values were displayed
as the range instead.
doi:10.1371/journal.pone.0114224.t001
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and right portal vein, respectively, so that all segments of the right lobe (segment 5
to 8) contained a ROI. Each ROI contained 301.9¡22.5 pixels. The vessels and
bile ducts were avoided as much as possible while drawing ROIs. Another 10 cm2
ROI was placed outside the body at the left upper corner of the representative
image containing the main portal vein, to measure noise. Pixel values for each
ROI were automatically extracted. A locally developed program written in C
language was used to calculate the mean value, standard deviation (SD), skewness,
and kurtosis. Corrected coefficient of variation (cCV), which was considered a
parameter that represents regional liver texture heterogeneity was calculated as
cCV 5 (SDliver- SDair)/SIliver 6100; where SDliver and SDair represent the SD of
signal intensities in the liver and air ROIs, respectively and SIliver is the mean
signal intensity in the liver [9]. Skewness is the degree of asymmetry of a
histogram; a histogram with a long tail to the right has a positive skewness value,
and a perfectly symmetric distribution has a skewness value of zero. Kurtosis is a
measure of peakedness; a histogram that is more peaked than a normal
distribution has a positive kurtosis value, and a normal distribution has a kurtosis
of zero [12]. Through this process, each patient generated four data sets of cCV,
skewness, and kurtosis acquired from the four sets of ROIs (SetROI), respectively.
Set1 and set2 each represented data acquired from the ROI placed at segment 5
and segment 6 (drawn on the representative image including the main portal
vein), (Figure 3) and set3 and set4 represented those of segment 8 and segment 7
(drawn on the representative image including horizontal portion of the right
hepatic vein). For comparison, mean values (Setaverage) of cCV, skewness, and
kurtosis were calculated by averaging the values from the four sets of ROIs.
Statistical analysis
We used SPSS version 20.0 for Windows (Chicago, Ill, USA) to perform ANOVA
of cCV, skewness, and kurtosis. The four ROI data sets (setROI) were considered as
clustered data, and were separately analyzed according to different fibrosis grades.
In parallel, we analyzed the averaged values of cCV, skewness, and kurtosis
(setaverage). We speculated that if the parameters generated from each data set
produced similar profiles, then their averaged value (setaverage) could represent all
four ROIs, and thus the individual patient. Multi-group comparison analysis
(LSD test) was performed for setaverage if P,0.05 by ANOVA. Univariable and
multivariable (adjusted for bilirubin, AST, and ALT) multiple linear regression
analysis were performed using SAS version 9.2 (SAS Institute, Cary, NC, USA) for
parameters that were suggested to be significantly (P,0.05) associated with
fibrosis grade by ANOVA.
Next, the diagnostic performance of differentiating between fibrosis grades was
assessed by calculating the areas under the receiver operating characteristic curves
(ROC) of parameters (setaverage) with P,0.05 by ANOVA using SPSS program.
An area under the curve of 1.0 is characteristic of an ideal test, whereas 0.5
indicates a test of no diagnostic value. Significance was accepted for differences
with P values less than 0.05.
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Results
The number of patients in each pathologic fibrosis stage was 11, 20, 13, 15, and 46
for F0, F1, F2, F3, and F4, respectively. Representative histograms of normal and
hepatic fibrosis are shown in Figure 4. Histograms based on ROI data obtained
from fibrosis-free livers showed a tall and sharp peak and the overall outline of the
graph appeared narrow and slender. In contrast, the histograms of fibrotic livers
were relatively blunted with shorter peaks, and the outline of the graph itself was
relatively wider, and the fibrosis grade (or amount of fibrosis) seemed to affect the
overall shape of the graph (Figure 4). The measured values of cCV, skewness, and
kurtosis obtained from all four sets of ROI (Figure 5A) and mean value obtained
from setaverage (Figure 5B) were each plotted according to the fibrosis grades.
Univariable analysis by ANOVA according to different fibrosis grades
demonstrated statistically significant differences in cCV of all four ROI data sets
and setaverage (P,0.001), but not skewness or kurtosis (Table 2). Multi-group
comparison tests (LSD) for cCV of setaverage revealed that F4 was significantly
different from all other grades, while cCV of F0 differed from those of F2, 3, and 4
(Table 2).
Univariable linear regression analysis showed that cCV was significantly
associated with fibrosis grades (P,0.001) for each setROI and setaverage. For
setaverage, b and standard error were 0.40 and 0.06, respectively (Table 3).
Multivariable linear regression analysis of setaverage adjusted for bilirubin, AST,
and ALT showed b and standard error of 0.36 and 0.07, respectively (Table 3).
ROC curves were used to assess the overall diagnostic performance of cCV
obtained from setaverage in predicting different degrees of fibrosis (Figure 6).
Fibrosis grade 4 was most easily distinguishable from the other fibrosis grades,
with an area under ROC score of 0.857, standard deviation 0.036, and 95%
confidence interval 0.785–0.928 (Table 4).
Figure 3. An example showing how we placed the ROIs (red circles) at segment 5 and segment 6
(drawn on the representative image including the main portal vein). Two more ROIs were placed at
segment 7 and segment 8 at the level including horizontal portion of the right hepatic vein.
doi:10.1371/journal.pone.0114224.g003
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Discussion
In the current study, we demonstrated that texture analysis of routine gadoxetic
acid-enhanced MRI can be applied to quantitatively measure the degree of liver
parenchyma fibrosis. Among cCV, skewness and kurtosis, cCV was significantly
associated with fibrosis grade. The cCV is a parameter that reflects heterogeneity
and may be utilized to predict fibrosis grade. The cCV remained significant even
on multivariable analysis performed to analyze the effect of AST, ALT, and
bilirubin. These observations are consistent with a preliminary study which
suggested that histogram analysis may be beneficial in predicting liver cirrhosis
[13].
Considerable progress in non-invasive measurement of hepatic fibrosis has
been achieved by specialized imaging methods [1, 14]. However, methods such as
ultrasound transient elastography and MR elastography require dedicated
equipment and additional procedures, which raise problems of limited access,
Figure 4. Representative cases of (A) 20 year old male (living-related healthy liver transplantation donor, F0), (B) 37 year old male (hepatocellular
carcinoma, F2), (C) 57 year old male (hepatocellular carcinoma, F4), and (D) 54 year old male (hepatocellular carcinoma, F4). Histology images of
Eosin and Masson-Trichrome stain, 640 (upper row), hepatobiliary phase images of gadoxetic acid-enhanced MRI (middle row), and the histogram
produced by plotting each pixel acquired from all four ROI sets according to signal intensity (x-axis) and frequency (y-axis) (lower row).
doi:10.1371/journal.pone.0114224.g004
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increased work-load, and medical expenses. MR spectroscopy is another
promising non-invasive technique, however at the current stage there seems to be
ongoing debate on its role on measuring hepatic fibrosis [14–17]. Meanwhile, MR
spectroscopy has a high demand on operator skills and equipment and therefore
raise concerns on feasibility [14].
Therefore, it would be meaningful if fibrosis measurement can be integrated
into the diagnostic workflow of routine imaging studies. Several studies have
attempted to evaluate fibrosis using hepatobiliary phase images of gadoxetic acid-
enhanced MRI [5–7, 18, 19]. As described in an experiment using rats, the activity
of organic anion-transporting peptide 1 is reduced while that of multidrug
resistance-associated protein 2 is up-regulated [20], which could account for
hepatic damage and cirrhosis resulting in a relatively decreased liver signal
[21, 22]. In an experimental study in rats, negative correlation between advanced
Figure 5. (A) Box plot graphs depicting the profile of cCV (left), skewness (middle), and kurtosis (right) obtained from all four ROI sets and (B)
mean values obtained from setaverage are displayed according to fibrosis grades.
doi:10.1371/journal.pone.0114224.g005
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fibrosis and the signal intensity of gadoxetic acid was observed [23]. These
observations were further expanded into other studies which mainly used ‘relative
enhancement’ to predict liver fibrosis with or without internal standards such as
spleen, muscle, and others [5–7, 19, 24]. However, we speculated that ‘relative
enhancement’ could be a context-dependent parameter and fluctuate for several
reasons, and thus potentially not suitable for comparison or quantification.
Firstly, the liver signal intensity and the concentration of gadoxetic acid do not
demonstrate a linear relationship, and the relaxivity of gadoxetic acid differs in
water, blood, and liver [25, 26]. Secondly, genetic polymorphism [27, 28] and
inter-individual variability in the hepatocyte transporter expression and function
Table 2. ANOVA according to fibrosis grades to compare cCV, skewness, and kurtosis from each set of ROI and the set of averaged values obtained from
each set, respectively.
Parameter SetROI Fibrosis grade P value
0 1 2 3 4
cCV Set1 2.14 3.06 3.35 3.30 5.45 ,0.001
Set2 2.10 3.38 3.50 3.40 5.27 ,0.001
Set3 2.30 3.30 3.95 3.82 5.77 ,0.001
Set4 2.23 3.36 4.27 3.69 5.59 ,0.001
Setaverage 2.19 3.28 3.77 3.55 5.52 ,0.001
*Fibrosis grades with difference for
setaverage
2,3,4 4 4 4 0,1,2,3
Skewness Set1 20.17 20.05 20.04 20.01 20.02 0.775
Set2 0.04 20.02 20.19 20.07 20.01 0.360
Set3 20.03 0.08 0.05 20.17 0.05 0.178
Set4 20.12 20.06 0.04 0.01 0.06 0.635
Setaverage 20.07 20.06 20.04 20.06 0.02 0.518
Kurtosis Set1 2.94 3.30 3.12 3.11 3.00 0.517
Set2 3.12 3.56 2.88 3.20 3.16 0.393
Set3 2.90 3.17 2.88 3.14 2.96 0.317
Set4 3.22 3.13 3.25 2.88 3.26 0.597
Setaverage 3.05 3.29 3.03 3.08 3.09 0.353
*Multiple comparison test (LSD) was performed on the set of averaged value if P,0.05 by ANOVA.
doi:10.1371/journal.pone.0114224.t002
Table 3. Univariable and multivariable (adjusted for bilirubin, AST, and ALT) linear regression analysis for predicting fibrosis grade by cCV measured on
hepatobiliary phase MRI.
Univariable analysis Multivariable analysis
b (standard error) P-value b (standard error) P-value
Set1 0.34 (0.05) ,0.001 0.30 (0.06) ,0.001
Set2 0.34 (0.06) ,0.001 0.30 (0.06) ,0.001
Set3 0.38 (0.06) ,0.001 0.35 (0.06) ,0.001
Set4 0.36 (0.06) ,0.001 0.32 (0.07) ,0.001
Setaverage 0.40 (0.06) ,0.001 0.36 (0.07) ,0.001
doi:10.1371/journal.pone.0114224.t003
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can influence the baseline level of gadoxetic acid uptake by hepatocytes
[26, 29, 30]. Thirdly, the function of transporters and the clearance of contrast
agent can be influenced by blood flow, transmembrane barriers [26], and drug-
drug interaction with co-administrated drugs metabolized by the liver [31] or
deranged blood chemistry levels [19]. Therefore, we speculated that to achieve
more consistent quantifications, we should focus on the distribution rather than
Figure 6. Receiver operating characteristic curve testing the ability to differentiate METAVIR fibrosis grade (A) F4 from F0-3, (B) F3-4 from F0-2, (C)
F3-4 from F0-1, and (D) F1-4 from F0, based on the cCV value obtained setaverage.
doi:10.1371/journal.pone.0114224.g006
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the degree of enhancement, and hypothesized that texture analysis of the liver
could be useful to depict the distribution of functioning hepatocytes and non-
functional fibrotic tissue.
Image texture refers to the distribution of brightness and darkness (gray tones)
within an image. Visual evaluation of texture can often be particularly subjective
and human perception of subtle diagnostic information is limited. Texture
analysis can assess the spatial location and signal intensity of each pixel in the ROI,
which can be useful to decrease mistakes in making clinical decisions and
interpreting equivocal cases [32, 33]. The signal intensity of each pixel on
hepatobiliary phase is determined by the relaxation rate influenced by the
hepatobiliary compartment and blood/extravascular extracellular space (EES)
compartment (which includes fibrosis), namely, DR1Liver 5 (1-QLiver)
DR1Hepatobiliary + QLiverDR1Blood&EES, (DR1, relaxation rate; QLiver, total tissue water
content in the liver, approximately 0.23 in standard human subjects) [34]. On
hepatobiliary phase images of healthy subjects, gadoxetic-acid enhanced MR
displays a homogeneously bright liver due to abundant hepatocytes that actively
uptake gadoxetic acid. Meanwhile EES, which negatively contribute to enhance-
ment, is scant and mostly negligible. Therefore, most pixels will appear bright with
relatively little degree of variation. However, as fibrosis progresses and replaces
functional hepatocytes, the enhancement of each pixel would become hetero-
geneous. A wide spectrum can be expected, with pixels corresponding to
functioning hepatocytes (bright dots) and dense fibrosis (dark dots) at the
extremes. Intermingled hepatocytes and fibrosis would appear as gray pixels. We
believe that histogram analysis can be useful to describe such enhancement
heterogeneity, which ultimately represents the degree of fibrosis.
Although histologic evaluation based on liver biopsy is the reference method for
liver fibrosis grading, theoretically it has several limitations. It has been reported
that biopsy assessment can underestimate the degree of hepatic fibrosis [35]. The
currently used histologic fibrosis grading systems assess the extent of fibrosis [36–
38], and can be considered qualitative methods. As chronic hepatitis proceeds,
fibrosis first appears in portal areas, progresses to periportal zones, and finally
extends to other portal tracts and terminal hepatic venules. Portocentral septa
formation is considered to be indicative of advanced fibrosis than portoportal
septa, but differentiating these patterns could be challenging [38, 39].
Theoretically this approach can be somewhat insensitive to the actual amount of
Table 4. The diagnostic performance of cCV in predicting fibrosis grades by ROC analysis.
Area under ROC Standard deviation 95% confidence interval
F0-3 vs. F4 0.857 0.036 0.785–0.928
F0-2 vs. F3-4 0.813 0.041 0.732–0.893
F0-1 vs. F2-4 0.826 0.043 0.741–0.910
F0 vs. F1-4 0.831 0.067 0.700–0.961
ROC, receiver operating characteristic.
doi:10.1371/journal.pone.0114224.t004
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fibrosis, because even if the extent is similar, the density of fibrosis deposition
could be variable. For instance, histological grading systems will not differentiate
the severity of fibrosis burden once a patient is diagnosed with liver cirrhosis
(fibrosis grade 4 by METAVIR system). In our study, even among liver cirrhosis
(F4) patients, those with more abundant fibrosis showed more severely blunted
and widely spread out histogram patterns (Figure 4C and 4D), suggesting that the
histogram pattern could correlate with fibrosis burden. Therefore, we believe that
our method might be applicable as a quantitative liver fibrosis scale.
This study has several limitations. First, in spite of the statistically significant
difference observed, the measured cCV value showed considerable overlap among
different fibrosis grades. Subsequent studies to further improve predictive power
and accuracy, such as higher resolution images, volumetric acquisition of
histograms, and/or refining the pulse sequence is necessary. The influence of
modulating the imaging parameters (e.g. flip angle) as well should be further
examined. Second, we did not assess whether other types of infiltrative pathologies
such as fatty liver, hepatitis, sinusoid obstructive syndrome or metabolic disorders
will influence the histogram analysis. Third, the study population was somewhat
arbitrary and includes the possibility of selection bias, because it was recruited by
a retrospective approach according to the MR unit used for image acquisition.
Fourth, we did not compare the diagnostic performance of our texture analysis
method with those of other non-invasive imaging parameters described to reflect
hepatic fibrosis such as relative enhancement.
In conclusion, histogram analysis of the hepatobiliary phase images of
gadoxetic acid-enhanced MRI can provide non-invasive quantitative evaluation
of hepatic fibrosis. This method is feasible as it does not require additional
sequences and is based on simple calculations. Therefore we believe that this
method of liver fibrosis measurement can be integrated into routine gadoxetic
acid-enhanced MR studies.
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